Alvotech Files 6-K Report

Ticker: ALVOW · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1898416

Alvotech 6-K Filing Summary
FieldDetail
CompanyAlvotech (ALVOW)
Form Type6-K
Filed DateOct 10, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, 6-K, foreign-private-issuer

TL;DR

Alvotech filed a 6-K on 10/10/24, confirming its 20-F reporting status. Standard update.

AI Summary

Alvotech, a biopharmaceutical company, filed a Form 6-K on October 10, 2024. The filing is a report of a foreign private issuer and indicates that Alvotech files its annual reports under cover of Form 20-F. The company's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.

Why It Matters

This filing provides routine updates for investors regarding Alvotech's status as a foreign private issuer and its reporting obligations.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain material new financial or operational information.

Key Players & Entities

  • Alvotech (company) — Registrant
  • 001-41421 (company) — SEC File Number
  • October 10, 2024 (date) — Filing Date
  • 9, Rue de Bitbourg, L-1273 Luxembourg (location) — Principal Executive Office

FAQ

What type of filing is this for Alvotech?

This is a Form 6-K, a Report of Foreign Private Issuer.

When was this Form 6-K filed?

The filing was made on October 10, 2024.

Does Alvotech file annual reports under Form 20-F or 40-F?

Alvotech indicates it files annual reports under cover of Form 20-F.

Where is Alvotech's principal executive office located?

Alvotech's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.

What is Alvotech's SIC code?

Alvotech's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Stats: 331 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-10-10 13:35:06

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alvotech (Registrant) Date: October 10, 2024 /s/ Tanya Zharov Tanya Zharov General Counsel

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.